Orchard Therapeutics and SIRION Biotech announced the entry into a license agreement, pursuant to which Orchard has licensed SIRION’s LentiBOOST technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo autologous hematopoietic stem cell gene therapy drug candidates. Under the terms of the agreement, SIRION will provide Orchard with a license to its proprietary lentiviral transduction enhancer LentiBOOST for development and commercialization activities for select Orchard programs. SIRION will be entitled to upfront and milestone payments and is eligible to receive royalties on net sales of future products that utilize the LentiBOOST technology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.